Healome Therapeutics is a Birmingham (UK) based healthcare company developing treatments for restoring function in diseased and damaged tissues, with a current focus on ocular surface diseases. We engineer and locally deliver 'pro-healing' micro-environments to tackle some of the most notoriously challenging conditions known to have biological, chemical and physical drivers or pose significant drug delivery and retention challenges. Our current therapies in the ocular surface disease area behave like a clear bandage you apply and forget about like a normal eye drop. Our mission in eye care is to drive big advancements in how eye conditions with a disproportionately huge impact on quality of life are treated in the clinic and managed by patients within their daily lives. We aim to create products offering more effective and longer lasting relief, that address drivers of the condition, and that are practical to use by patients and clinicians. In doing so, we will support healthcare systems to address future eye health challenges sustainably and to empower people to lead healthier and more independent lives. Twitter: https://twitter.com/healome_tx | @healome_tx
Location: United Kingdom
Employees: 1-10
Total raised: $2.88M
Founded date: 2021
Investors 1
| Date | Name | Website |
| 28.03.2023 | Startup Fu... | sfccapital... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.07.2026 | Seed | $2.67M | Startup Fu... |
| 20.10.2021 | Pre-Seed | $206.9K | - |
Mentions in press and media 4
| Date | Title | Description |
| 11.07.2026 | Healome Therapeutics Secures £2M to Revolutionize Eye Care with Advanced Matrix Technology | Healome Therapeutics, a UK spinout, secured £2M seed funding. Its proprietary eye-drop matrix technology promises to transform ocular surface disease treatment. This innovation delivers sustained drug action, improving retention, lubricatio... |
| 07.07.2026 | Healome Therapeutics Closes £2 Million Seed Round Led by Empirical Ventures to Advance Eye-Drop Matrix Technology for Ocular Surface Diseases | BIRMINGHAM, England, July 7, 2026 /PRNewswire/ -- Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has closed a GBP£2 million ove... |
| 07.07.2026 | Healome Therapeutics Closes £2M Seed Funding | Healome Therapeutics, a University of Birmingham (UK) spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, closed a GBP£2m seed financing round. The round was led by Empirical Ventures, with participation... |
| - | Healome Therapeutics | “Healome Therapeutics develops novel treatments for restoring function in diseased and damaged tissues, with a current focus on ocular surface diseases. ” |